Putnam Investments’s Royalty Pharma RPRX Stock Holding History

Putnam Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$31.1M	Buy	+1,105,967	New	+$30.4M	0.04%	173
2021 Q1	–	Sell	-664,679	Closed	-$33.3M	–	834
2020 Q4	$33.3M	Sell	664,679 -339,400	-34%	-$14.4M	0.06%	194
2020 Q3	$42.2M	Buy	1,004,079 +241,500	+32%	+$10.4M	0.08%	166
2020 Q2	$37M	Buy	+762,579	New	+$37.7M	0.08%	166

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments's RPRX Position: Q4 2023 in Review

Putnam Investments opened a new position in Royalty Pharma (RPRX) in Q4 2023: 1,105,967 shares worth $31.1M. The stake represents 0.04% of the portfolio and ranks #173 among its holdings. This is a return to the name: Putnam Investments previously reported a position in RPRX as recently as Q4 2020.

Putnam Investments first reported a position in RPRX in Q2 2020 and has held it in 4 quarters since. The position peaked at $42.2M in Q3 2020. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

Putnam Investments held 1,105,967 shares of Royalty Pharma worth $31.1M as of Q4 2023.
Royalty Pharma was a new Putnam Investments position in Q4 2023.
Royalty Pharma made up 0.04% of Putnam Investments's portfolio in Q4 2023, its #173 holding.
Putnam Investments first reported a position in Royalty Pharma in Q2 2020 and has held it in 4 quarters since.
Putnam Investments's Royalty Pharma position peaked at $42.2M in Q3 2020.
363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.